Muscle Invasive Bladder Cancer Archives - Page 3 of 9

Bladder Cancer Journal Vol. 10, Issue 1

by Bladder Cancer Journal | Mar 2024

Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle...

Bladder Cancer Journal Vol. 9, Issue 4

by Bladder Cancer Journal | Dec 2023

What is a Bladder Cancer Molecular Subtype? Abstract: BACKGROUND: Several molecular...

Bladder Cancer Journal Vol. 9, Issue 3

by Bladder Cancer Journal | Sep 2023

Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is...

Bladder Cancer Journal Vol. 9, Issue 2

by Bladder Cancer Journal | Jun 2023

Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer...

Neoadjuvant Therapy for MIBC in the Genomic Era

by Colin P. N. Dinney, MD | May 2023

Colin P.N. Dinney, MD, discusses the promise of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the genomic era.

Prioritizing the Optimal Therapy for T1 Bladder Cancer: Using the Old and the New to Determine What to Do

by Seth P. Lerner, MD | Apr 2023

Seth P. Lerner, MD, discusses the optimal therapy for T1 high-grade (T1HG) bladder cancer and considers the future of treatment.

Bladder Cancer Journal Vol. 9, Issue 1

by Bladder Cancer Journal | Mar 2023

Recent Advances in the Classification of Bladder Cancer – Updates from the 5th Edition of the...

Bladder Sparing Regimens for Muscle Invasive Disease: Should We Be Doing this More?

by Peter Black, MD, FACS, FRCSC | Mar 2023

Peter Black, MD, FACS, FRCSC, discusses trimodal therapy (TMT) as a bladder-sparing option for some patients with muscle-invasive bladder cancer (MIBC).

The Contribution of SWOG to Bladder Cancer Clinical Trials

by Seth P. Lerner, MD | Mar 2023

Seth P. Lerner, MD, provides a comprehensive history of Bacille Calmette-Guerin (BCG) and SWOG ’s innovation in bladder cancer over the past three decades.

Risk-Adapted TURBT

by Seth P. Lerner, MD | Feb 2023

In this 20-minute video, Seth P. Lerner, MD, Professor of Urology and Vice-chair for Faculty Affairs in the Scott Department of Urology, and Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program at Baylor University, discusses risk-adapted transurethral resection of bladder tumor (TURBT). He assesses TURBT’s role in staging and treatment and considers its use in bladder preservation.